

4. Central Nervous System

Contents

- [4.1 Hypnotics and anxiolytics](#)
- [4.2 Drugs used in psychoses and related disorders](#)
- [4.3 Antidepressant drugs](#)
- [4.4 CNS stimulants and drugs used for attention deficient hyperactivity disorder](#)
- [4.5 Drugs used in the treatment of obesity](#)
- [4.6 Drugs used in nausea and vertigo](#)
- [4.7 Analgesics](#)
- [4.8 Antiepileptics](#)
- [4.9 Drugs used in Parkinsonism and related disorders](#)
- [4.10 Drugs used in substance dependence](#)
- [4.11 Drugs for dementia](#)

Key

	<p>Red drug see GMMMG RAG list <i>Click on the symbols to access this list</i></p>
	<p>Amber drug see GMMMG RAG list <i>Click on the symbols to access this list</i></p>
	<p>Green drug see GMMMG RAG list <i>Click on the symbols to access this list</i></p>
U	<p>If a medicine is unlicensed this should be highlighted in the template as follows Drug name U</p>
	<p>Not Recommended</p>
OTC	<p>Over the Counter In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement.</p>
Order of Drug Choice	<p>Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order.</p>

BNF chapter	4	Central Nervous System
Section	4.1	Hypnotics and Anxiolytics
Subsection	4.1.1	Hypnotics
	NICE TA77: Insomnia - newer hypnotic drugs	
First choice	Zopiclone tablets: 3.75mg, 7.5mg	For short term use, licensed for max of 28 days.
Alternatives	Zolpidem tablets: 5mg, 10mg	For short term use, licensed for max of 28 days.
	Temazepam tablets: 10mg oral solution 10mg/5ml	MHRA DSU: Drugs and driving: blood concentration limits set for certain drugs, Feb 2015
	Melatonin prolonged-release tablets: 2mg (Circadin®) For REM sleep behaviour disorder in Parkinson's disease	 following specialist advice NICE NG71: Parkinson's disease in adults
Do Not Prescribe	Melatonin For management of jet lag	Criterion 1 (see RAG list) GMMMG Travel Abroad policy
Subsection	4.1.2	Anxiolytics
Benzodiazepines are indicated for short-term relief of severe or disabling anxiety only		
NICE CG113: Generalised anxiety disorder and panic disorder in adults		
First choice	Diazepam tablets: 2mg, 5mg, 10mg oral solution: 2mg/5ml	MHRA DSU: Drugs and driving: blood concentration limits set for certain drugs, Feb 2015 MHRA DSU: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression, March 2020
Do Not Prescribe	Meprobamate  tablets	Criterion 1 (see RAG list)

BNF chapter	4 Central Nervous System
Section	4.2 Drugs used in psychoses and related disorders
	NICE CG178: Psychosis and schizophrenia in adults NG181: Rehabilitation for adults with complex psychosis NICE CG185: Bipolar disorder GM Shared Care Guideline: Oral second generation (atypical) antipsychotics for adults
Subsection	4.2.1 Antipsychotic drugs
First choice	<p>Aripiprazole tablets: 5mg, 10mg, 15mg</p> <p>A for licensed indications and also unlicensed when recommended by NICE R Use in dementia U (For new patients only). Check local commissioning arrangements NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15-17</p>
	<p>Haloperidol tablets: 1.5mg, 5mg, 10mg, 20mg oral solution: 5mg/5ml, 10mg/5ml</p> <p>Gn for palliative care use only MHRA DSU: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium, Dec 2021</p>
	<p>Olanzapine tablets: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg orodispersible tablets: 5mg, 10mg, 15mg, 20mg</p> <p>A for licensed indications and also unlicensed when recommended by NICE R Use in dementia U (For new patients only). Check local commissioning arrangements</p>
	<p>Quetiapine tablets: 25mg, 100mg, 150mg, 200mg, 300mg</p> <p>A for licensed indications and also unlicensed when recommended by NICE R Use in dementia U (For new patients only). Check local commissioning arrangements</p>
	<p>Risperidone tablets: 500microgram, 1mg, 2mg, 3mg, 4mg, 6mg orodispersible tablets: 500microgram, 1mg, 2mg, 3mg, 4mg oral solution: 1mg/1ml</p> <p>A for licensed indications and also unlicensed when recommended by NICE R Use in dementia (For new patients only). Check local commissioning arrangements</p>

		MHRA (2013): Risperidone and paliperidone: risk of floppy iris syndrome
Alternatives	Amisulpride tablets: 50mg, 100mg, 200mg, 400mg oral solution: 100mg/ml	A for licensed indications and also unlicensed when recommended by NICE R Use in dementia U (For new patients only). Check local commissioning arrangements
	Aripiprazole tablets: 30mg orodispersible tablets: 10mg, 15mg	A for licensed indications and also unlicensed when recommended by NICE R Use in dementia U (For new patients only). Check local commissioning arrangements NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15-17
	Chlorpromazine tablets: 25mg, 50mg, 100mg	Gn for palliative care use only
	Clozapine tablets: 25mg, 50mg, 100mg, 200mg	R MHRA DSU: Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus, Oct 2017 MHRA DSU: Clozapine and other antipsychotics: monitoring blood concentrations for toxicity, Aug 2020
	Levomepromazine tablets: 25mg (do not prescribe 6mg tablets)	Gn for palliative care use only
	Quetiapine MR tablets: 50mg, 150mg, 200mg, 300mg, 400mg	MR formulation is restricted for use as adjunct in depression only A Licensed indications and also unlicensed indications as recommended by NICE R Use in dementia U (For new patients only). Check local commissioning arrangements

Grey drugs Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population	Cariprazine Capsules: 1.5mg, 3mg, 4.5mg, 6mg For treatment of schizophrenia in adults aged 18 years and older with negative symptoms, where at least 2 generic antipsychotics (such as amisulpride, olanzapine, risperidone, aripiprazole or clozapine) have been trialled and have failed.	 pending production of a shared care protocol Criterion 2 (see RAG list)
	Lurasidone Tablets: 18.5mg, 37mg, 74mg Only for the treatment of schizophrenia in adults aged 18 years and older who require antipsychotic treatment, who have previously had a trial of but not responded to aripiprazole, and who fulfil one of the following criteria: <ul style="list-style-type: none"> • Patient gained weight on other antipsychotics and there is a need for the BMI to move towards the normal range • Patients for whom there is a need to avoid weight gain and metabolic adverse effects, e.g. patients with diabetes, cardiovascular disease • Patients with a prolonged QTc interval 	 pending production of a shared care protocol Criterion 2 (see RAG list)
Do Not Prescribe	Haloperidol 500 microgram tablets	Criterion 2 (see RAG list)
	Loxapine Inhalation powder	Criterion 1 (see RAG list)
Subsection	4.2.2 Antipsychotic depot injections  Only for those patients who are stable and if SCP available; or if under the care of a community psychiatric nurse. In some localities there may be commissioning arrangements in place to permit step down.	
First choice	Flupentixol decanoate injection: 20mg/1ml concentrated injection 100mg/1ml low volume injection 200mg /1ml	 See above
	Zuclopenthixol decanoate injection: 200mg/1ml, 500mg/1ml	 See above MHRA DSU: Drug name confusion, April 2013
Alternatives	Risperidone injection vial (Risperdal Consta®): 25mg, 37.5mg, 50mg (powder for reconstitution)	 See above MHRA DSU: Drug name confusion, April 2013

		MHRA DSU: Risperidone and paliperidone: risk of floppy iris syndrome, Nov 2013
	<p>Haloperidol decanoate injection: 50mg/1ml, 100mg/1ml</p>	<p>A See above</p> <p>MHRA DSU: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium, Dec 2021</p>
	<p>Aripiprazole prolonged release injection (Abilify Maintena®) 400mg vial (with solvent)</p>	<p>A See above</p>
	<p>Paliperidone palmitate Prolonged-release suspension for injection 50mg, 100mg, 150mg (1 month depot) Prolonged-release suspension for injection 175mg, 263mg, 350mg, 525mg (3 month depot)</p>	<p>A see above</p> <p>MHRA DSU: Risperidone and paliperidone: risk of floppy iris syndrome, Nov 2013</p>

Subsection	4.2.3 Drugs for mania and hypomania	
Anti-manic drugs should be initiated by specialist mental health services		
First choice		
Lithium		
Preparations vary widely in bioavailability therefore prescribe by brand		
	<p>Lithium carbonate MR tablets: 200mg, 400mg (Priadel®)</p> <p>Lithium citrate oral solution: 520mg/5ml (Priadel®)</p>	<p>A</p> <p>NPSA (2009) Safer lithium prescribing</p>
Alternatives		
Benzodiazepines		
	May be helpful in initial stages of treatment for behavioural disturbances or agitation	See 4.1.2
Antipsychotic drugs		
	Antipsychotic drugs are useful in acute episodes of mania and hypomania.	See 4.2.1
First choice	<p>Olanzapine tablets: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg orodispersible tablets: 5mg, 10mg, 15mg, 20mg</p>	A Licensed indications and also unlicensed indications as recommended by NICE
	<p>Quetiapine tablets: 50mg, 150mg, 200mg, 300mg, 400mg</p>	A Licensed indications and also unlicensed indications as recommended by NICE
	<p>Risperidone tablets: 500microgram, 1mg, 2mg, 3mg, 4mg, 6mg orodispersible tablets: 500microgram, 1mg, 2mg, 3mg, 4mg oral solution: 1mg/1ml</p>	A Licensed indications and also unlicensed indications as recommended by NICE
Alternatives	<p>Aripiprazole tablets: 5mg, 10mg, 15mg, 30mg orodispersible tablets: 10mg, 15mg oral solution 1mg/1ml</p>	<p>A Licensed indications and also unlicensed indications as recommended by NICE</p> <p>NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar disorder</p>

<p>Haloperidol tablets: 500microgram, 1.5mg, 5mg, 10mg, 20mg oral solution: 5mg/5ml, 10mg/ 5ml</p>	<p>MHRA DSU: Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium, Dec 2021</p>
<p>Quetiapine modified release tablets: 50mg, 200mg, 300mg, 400mg</p>	<p>A Licensed indications and also unlicensed indications as recommended by NICE</p>
<p>Carbamazepine</p>	
<p>May be used under specialist supervision for the prophylaxis of bipolar disorder in patients unresponsive to a combination of other prophylactic drugs</p>	<p>Gn Following specialist initiation See 4.8.1</p>
<p>Valproate</p>	
<p>Sodium valproate is used for the treatment of manic episodes associated with bipolar disorder.</p>	
	<p>Sodium Valproate (Episenta®) capsules 150mg, 300mg</p> <p>Gn Following specialist initiation See 4.8.1</p> <p>MHRA DSUs: Valproate medicines (Epilim▼, Depakote▼): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met (April 2018) Valproate medicines (Epilim▼, Depakote▼): Pregnancy Prevention Programme materials online (May 2018) Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers (Sept 2018) Valproate medicines: are you in acting in compliance with the pregnancy prevention measures? (Dec 2018)</p>

BNF Chapter	4	Central Nervous System	
Section	4.3	Antidepressant drugs	
<p>NICE CG90: Depression in Adults</p> <p>NICE CG91: Depression in adults with a chronic physical health problem</p> <p>NICE CG192: Antenatal and postnatal mental health</p> <p>NICE CG26: Post traumatic stress disorder</p> <p>NICE CG113 Generalised anxiety disorder and panic disorder in adults</p>			
MHRA DSU: Antidepressants: risk of fractures, May 2010			
Subsection	4.3.1. Tricyclic and related antidepressants		
<p>Tricyclic antidepressants (TCAs) are not usually recommended as a first-line treatment for depression because they are associated with a greater risk of side effects than SSRIs or SNRIs and are generally more toxic in overdose</p>			
Tricyclic antidepressants			
		Lofepramine tablets: 70mg	
Alternatives		Clomipramine capsules: 10mg, 25mg, 50mg tablets M/R: 75mg	
Do Not Prescribe		Dosulepin  tablets, capsules Trimipramine tablets, capsules	<p>Criterion 1 (see RAG list)</p> <p>Criterion 2 (see RAG list)</p> <p>See also NHS England Items which should not be routinely prescribed in primary care: Guidance for CCGs</p>
Tricyclic-related antidepressants			
		Trazodone capsules: 50mg, 100mg tablets: 150mg	
Subsection	4.3.2. Monoamine-oxidase inhibitors (MAOIs)		
First Choice (reversible)		Moclobemide tablets: 150mg, 300mg	 following specialist initiation
Alternatives (non-reversible)		Phenelzine  tablets: 15mg	

Subsection	4.3.3. Selective serotonin re-uptake inhibitors	
First Choice	Sertraline tablets: 50mg, 100mg	
Alternatives	Citalopram tablets: 10mg, 20mg, 40mg oral drops: 40mg/ml	MHRA DSU (2016): Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use MHRA DSU: Citalopram and escitalopram: QT interval prolongation, Dec 2011
	Fluoxetine capsules: 20mg oral solution: 20mg/5ml	MHRA DSU: Fluoxetine: possible small risk of congenital cardiac defects, March 2010
Additional Notes NICE NG193: chronic pain in over 16s: assessment of all chronic pain and management of chronic primary pain MHRA DSU: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery, January 2021		
Subsection	4.3.4 Other antidepressant drugs	
First choice	Mirtazapine Tablets: 15mg, 30mg, 45mg Orodispersible tablets: 15mg, 30mg, 45mg	
Alternatives	Venlafaxine Tablets: 37.5mg, 75mg MR tablets: 37.5mg, 75mg, 150mg, 225mg	 specialist initiation for total daily doses \geq 300mg
	Duloxetine Capsules: 30mg, 60mg	NICE NG193: chronic pain in over 16s MHRA DSU: Duloxetine: regular assessment for suicidal ideation, Sept 2007
Grey drugs Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population	Duloxetine Capsules: 90mg, 120mg Only for use where the prescriber believes that patient's pill burden is high enough to justify the extra cost associated with the use of these formulations.	 Criterion 2 (see RAG list)

	<p>Agomelatine</p> <p>Tablets: 25mg</p> <p>Only for use when other antidepressants as recommended by NICE have failed.</p>	<p>G_n following specialist initiation</p> <p>Criterion 1 (see RAG list)</p>
	<p>Prazosin</p> <p>Tablets: 0.5mg and 1mg</p> <p>Only to be used for licensed indications and not for PTSD</p>	<p>G_n following specialist initiation</p> <p>Criterion 1 (see RAG list)</p>
	<p>Vortioxetine▼</p> <p>Tablets: 5, 10 and 20mg</p> <p>Only for treatment of major depressive episode in adults whose condition has responded inadequately to 2 antidepressants within the current episode</p>	<p>G_n following specialist advice</p> <p>NICE TA367: Vortioxetine for treating major depressive episodes</p> <p>Criterion 1 (see RAG list)</p>

Additional Notes

[MHRA DSU: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery, January 2021](#)

BNF Chapter	4	Central Nervous System
Section	4.4	CNS stimulants and drugs for attention deficit hyperactivity disorder
Subsection	ADHD adults	

[NICE CG72: Attention deficit hyperactivity disorder](#)

[NICE TA98: Methylphenidate, atomoxetine and dexamfetamine for ADHD in children and adolescents](#)

Drug treatment of ADHD should be part of a comprehensive treatment programme that addresses psychological, behavioural and educational or occupational needs.

First choice	<p>Methylphenidate U</p> <p>tablets: 5mg, 10mg, 20mg</p> <p>Modified release tablets</p> <p>Modified release capsules</p>	<p>U Unlicensed for treatment of adults</p> <p>A once patient stabilised as per SCG</p> <p>GM SCP: Atomoxetine, dexamfetamine, guanfacine, lisdexamfetamine and methylphenidate for ADHD In Adults</p> <p>Different modified release preparations may not have the same clinical effect therefore prescribers should specify the brand to be supplied.</p>
Alternatives	Atomoxetine	<p>A once patient stabilised as per SCG</p>

	capsules: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg	GM SCP: Atomoxetine, dexamfetamine, guanfacine, lisdexamfetamine and methylphenidate for ADHD In Adults MHRA DSU: Atomoxetine: increases in blood pressure and heart rate, Jan 2012
	Lisdexamfetamine capsules: 30mg, 50mg, 70mg	A once patient stabilised as per SCG GM SCP: Atomoxetine, dexamfetamine, guanfacine, lisdexamfetamine and methylphenidate for ADHD In Adults
Section	4.4 CNS stimulants and drugs for attention deficit hyperactivity disorder	
Subsection	CNS stimulants	
First choice	Modafinil tablets: 100mg, 200mg	R Pending approval of information for primary care prescribers for sleepiness associated with narcolepsy MHRA DSU: Modafinil now restricted to narcolepsy, March 2011 MHRA DSU: Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy, Nov 2020
	Dexamfetamine tablets: 5mg, 10mg, 20mg	R Treatment of narcolepsy, pending development of a shared care protocol.
	Solriamfetol tablets: 75mg, 150mg	R Excessive daytime sleepiness caused by narcolepsy NICE TA758: Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy
Do Not Prescribe	Modafinil For management of chronic shift work sleep disorder	Criterion 1 (see RAG list) MHRA DSU: Modafinil now restricted to narcolepsy, March 2011

BNF Chapter	4	Central Nervous System	
Section	4.5	Drugs used in the treatment of obesity	
Subsection	4.5.1	Anti-obesity drugs acting on the gastro-intestinal tract	
	NICE CG189: Obesity: identification, assessment and management of overweight and obesity in children, young people and adults		
First choice	Orlistat capsules: 120mg		
Alternative	Liraglutide (Saxenda®) solution for injection		R NICE TA664: Liraglutide for managing overweight and obesity
Do Not Prescribe	Naltrexone/bupropion (Mysimba®) prolonged-release tablets		Criterion 2 (see RAG list)

BNF Chapter	4	Central nervous system
Section	4.6	Drugs used in nausea and vertigo
Vomiting in pregnancy		
RCOG: The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) NICE NG201: Antenatal care		
First choice	Cyclizine U tablets: 50mg	
Alternatives	Prochlorperazine U tablets: 5mg	
	Metoclopramide U tablets: 10mg	MHRA DSU: Metoclopramide: risk of neurological adverse effects, Aug 2013
Grey drugs Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population	Doxylamine/pyridoxine tablets: 10mg/10mg (Xonvea®) To be used only when the other preparations currently recommended by RCOG guidance have been tried and have failed. This recommendation will be reviewed once guidance from RCOG, NICE and/or RMOG is available.	G_n Criterion 1 (see RAG list)
Postoperative nausea and vomiting		
	Local centres may have variations within their local postoperative nausea and vomiting guidelines.	
First choice	Cyclizine tablets: 50mg	
	Prochlorperazine tablets: 5mg buccal tablets: 3mg	
Alternatives 5HT₃- receptor antagonists	Granisetron tablets: 1mg	R post-op or following chemotherapy
	Ondansetron tablets: 4mg, 8mg	R post-op or following chemotherapy G_n For exceptional use in non oncology patients with chronic emesis following consultant recommendation and where all other options have failed

Vertigo / Meniere's		
First choice	Betahistine tablets: 8mg, 16mg	Do not offer betahistine to treat tinnitus (see NICE NG155, recommendation 1.5.5)
Alternatives	Cinnarizine tablets: 15mg	
	Prochlorperazine tablets :5mg buccal tablets: 3mg	Acute symptoms only
Hypersalivation / sialorrhea		
First choice	Hyoscine hydrobromide chewable tablets: 150 microgram, 300 microgram patches: 1mg/72 hours	
Motion sickness		
Do Not Prescribe	Travel sickness	In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement .
Cannabinoids		
	Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) oromucosal spray: 2.7 mg THC and 2.5 mg CBD per 100 microlitre actuation (Sativex®)	R NICE NG144: Cannabis-based medicinal products
Grey drugs Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population	Nabilone capsules: 250 micrograms, 1mg When used within marketing authorisation, i.e. for the control of nausea and vomiting caused by chemotherapeutic agents used in the treatment of cancer, in patients who have failed to respond adequately to conventional antiemetic treatments.	R Criterion 3 (see RAG list)
Do Not Prescribe	Cannabis-derived, cannabis-based and hemp products With the exception of nabilone (see above) and Epidyolex® (see chapter 4.8.1), when used within their marketing authorisations	Criterion 1 (see RAG list)

	Nabilone For all unlicensed indications	<u>Criterion 1 (see RAG list)</u>
--	---	-----------------------------------

BNF Chapter	4	Central nervous system
Section	4.7	Analgesics
Subsection	4.7.1	Non-opioid analgesics and compound analgesic preparations
Compound analgesic preparations that contain a simple analgesic (such as paracetamol) with an opioid component reduce the scope for effective titration of the individual components and are not recommended		
First choice	Paracetamol tablets: 500mg	
Alternatives	Paracetamol capsules: 500mg soluble tablets: 500mg oral suspension: 250mg/5ml suppositories: 500mg, 1g	
	Co-codamol  tablets 30mg/500mg soluble tablets 30mg /500mg	
Grey drugs Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population	Nefopam tablets: 30mg Only to be used in those patients with moderate to severe chronic liver disease who require analgesia stronger than paracetamol in whom NSAIDS and moderate strength opiates are contraindicated	
Do Not Prescribe	Co-proxamol tablets Paracetamol with tramadol tablets, effervescent tablets Paracetamol mixture / mucilage 500 mg/5 mL for topical use in patients with sore mouth or throat resulting from cancer treatment	
	Criterion 1 (see RAG list) <u>See also NHS England Items which should not be routinely prescribed in primary care: Guidance for CCGs</u>	
	Criterion 2 (see RAG list) <u>See also NHS England Items which should not be routinely prescribed in primary care: Guidance for CCGs</u>	
		Criterion 1 (see RAG list)

Do Not Prescribe	Aspirin with codeine (Co-codaprin) tablets, dispersible tablets	<u>Criterion 2 (see RAG list)</u>
	Electromagnetic pulse therapy (Actipatch®) Medical device	<u>Criterion 1 (see RAG list)</u>
	Minor conditions associated with pain, discomfort and/or fever e.g. aches and sprains, headache, period pain, back pain Mild toothache/teething Paracetamol, ibuprofen, teething gels See <u>commissioning statement</u> for exceptions	In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see <u>GM commissioning statement</u> .
	Ketamine Oral solution U	R for use in short courses as an opiate-sparing agent. Unlicensed special.
<p>Additional Notes</p> <p>For options on non-steroidal anti-inflammatory drugs (NSAIDs) please refer to Chapter 10: Musculoskeletal and joint diseases.</p> <p>NICE NG59: Low back pain and sciatica in over 16s: assessment and management</p>		

Subsection	4.7.2 Opioid analgesics	
	MHRA DSU: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression, March 2020 MHRA DSU: Opioids: risk of dependence and addiction, Sept 2020 GMMMG Opioid Prescribing for Chronic Pain: Resource Pack	
Weak opioid		
First choice	Codeine phosphate tablets: 15mg, 30mg, 60mg	
Alternatives	Dihydrocodeine tartrate tablets: 30mg	
Moderate opioid		
First choice	Tramadol hydrochloride capsules: 50mg	
Alternatives	Buprenorphine patch 7 days: 5 microgram / hour, 10 microgram / hour, 15 microgram/hour, 20 microgram / hour 4 days: 35 microgram/hour, 52.5 microgram/hour, 70 microgram/hour 3 days: 35 microgram / hour, 52.5 microgram, 70 microgram / hour	Buprenorphine patch: Different brands are NOT interchangeable Patches should be prescribed by brand as the frequency to be applied may vary between brands
Strong opioid		
	NICE CG140: Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults NICE NG46: Controlled drugs: safe use and management	
First choice	Morphine sulfate tablets: 10mg, 20mg, 50mg oral solution: 10mg/5ml MR capsules (12-hourly): 10mg, 30mg, 60mg, 100mg, 200mg MR tablets (12-hourly): 5mg, 10mg, 15mg, 30mg, 60mg, 100mg	MHRA DSU: Drugs and driving: blood concentration limits set for certain drugs, Feb 2015
Alternatives	Fentanyl (72 hourly) patches: 12 microgram/hour, 25 microgram/hour, 50 microgram/hour, 37.5 microgram/hour, 75 microgram/hour, 100 microgram/hour	MHRA DSU: Serious and fatal overdose of fentanyl patches, Sept 2008 MHRA DSU: Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children (Oct 2018) MHRA DSU: Transdermal fentanyl patches for non-cancer pain: do not use in opioid-naive patients, Sept 2020

	<p>Oxycodone hydrochloride capsules: 5mg, 10mg, 20mg oral solution: 5mg/5ml modified-release tablets: 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg, 120mg</p>	
<p>Grey drugs Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population</p>	<p>Fentanyl immediate release preparations Only to be used in patients undergoing palliative care treatment where the recommendation to use immediate release fentanyl is in line with NICE CG140 and has been made by a multi-disciplinary team and/or other healthcare professional with a recognised specialism in palliative care.</p>	<p>G_n following specialist initiation Criterion 2 (see RAG list) NHS England Items which should not be routinely prescribed in primary care: Guidance for CCGs</p>
	<p>Tapentadol Immediate-release & modified-release tablets Use of this agent should be restricted to those patients requiring treatment of severe chronic pain which CANNOT be managed with more established opioid therapies. Prescribers are reminded that NTS does not recommend the use of tapentadol over more established opioid therapies</p>	<p>G_n following specialist advice Criterion 2 (see RAG list)</p>
<p>Do Not Prescribe</p>	<p>Oxycodone with naloxone modified-release tablets</p>	<p>Criterion 2 (see RAG list) NHS England Items which should not be routinely prescribed in primary care: Guidance for CCGs</p>
	<p>Sufentanil sublingual tablets (Zalviso®)</p>	<p>Criterion 2 (see RAG list)</p>

Subsection	4.7.3 Neuropathic Pain	
GMMMG: Neuropathic Pain in Adults - Guideline for Primary Care NICE CG173: Neuropathic pain - pharmacological management		
First choice	Amitriptyline tablets: 10mg, 25mg, 50mg oral solution: 25mg/5ml, 50mg/5ml	NICE NG193: chronic pain in over 16s
	Nortriptyline U tablets: 10mg, 25mg	Unlicensed treatment. Nortriptyline can only be prescribed if amitriptyline is effective, however too sedative.
Alternatives	Gabapentin capsules: 100mg, 300mg, 400mg tablets: 600mg	Second line option if amitriptyline is ineffective, not tolerated or not suitable. MHRA DSU: Gabapentin (Neurontin): risk of severe respiratory depression, Oct 2017 MHRA DSU: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements, Apr 2019
	Pregabalin capsules: 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg	Only appropriate if gabapentin is effective but not tolerated due to side effects, i.e. third line use. MHRA DSU: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements, Apr 2019 MHRA DSU: Pregabalin (Lyrica): reports of severe respiratory depression, Feb 2021 MHRA DSU: Pregabalin (Lyrica): findings of safety study on risks during pregnancy, April 2022
	Duloxetine capsules: 30mg, 60mg	Duloxetine can be considered where other treatments have failed or where there is a history of substance misuse. May also be considered second line where there is a clear diagnosis of diabetic neuropathy
	Tramadol capsules: 50mg	Consider tramadol only if acute rescue therapy is needed for a short treatment duration in people awaiting referral to specialist pain services, after initial treatments have failed

Non-oral alternatives	<p>Capsaicin cream: 0.075% (Axsain®)</p>	<p>“Off-label” treatment recommended by NICE CG173 for localised neuropathic pain.</p>
<p>Grey drugs</p> <p>Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population</p>	<p>Gabapentin Pregabalin Capsules, tablets</p> <p>For management of chronic cough, only for patients in whom low dose morphine is unsuitable.</p>	<p>G_n following specialist advice</p> <p>Criterion 1 (see RAG list)</p> <p>MHRA DSU: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements, April 2019</p> <p>MHRA DSU: Gabapentin (Neurontin): risk of severe respiratory depression, Oct 2017</p> <p>MHRA DSU: Pregabalin (Lyrica): reports of severe respiratory depression, Feb 2021</p>
	<p>Lidocaine Medicated plasters: 700 mg</p> <p>Only to be used in patients who have been treated in line with NICE CG173 but are still experiencing neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia).</p>	<p>G_n</p> <p>Criterion 1 (see RAG list)</p> <p>GMMMG Neuropathic pain guideline</p> <p>NHS England Items which should not be routinely prescribed in primary care: Guidance for CCGs</p>
	<p>Capsaicin Cutaneous patch: 179mg (Qutenza®)</p> <p>Only to be used in adults with post-herpetic neuralgia (PHN) who have not achieved adequate pain relief from, or who have not tolerated, conventional first and second-line treatments.</p>	<p>R</p> <p>Criterion 2 (see RAG list)</p>
Do Not Prescribe	<p>Capsaicin Cutaneous patch: 179mg (Qutenza®)</p> <p>For all unlicensed indications (i.e. for all indications other than PHN).</p>	<p>Criterion 1 (see RAG list)</p>
	<p>Gabapentin topical U</p>	<p>Criterion 1 (see RAG list)</p>
	<p>Lidocaine medicated plasters: 700 mg</p> <p>For all off-label indications</p>	<p>Criterion 1 (see RAG list)</p>
Trigeminal neuralgia		
First choice	<p>Carbamazepine tablets: 100mg, 200mg, 400mg</p>	

Subsection	4.7.4 Antimigraine drugs	
	NICE CG150: Headaches GMMMG headache pathway	
Do Not Prescribe	Infrequent migraine See commissioning statement for exceptions	In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement .
4.7.4.1 Treatment of acute migraine		
<p>NICE CG150 (1.2.7) Be alert to the possibility of medication overuse headache in people whose headache developed or worsened while they were taking the following drugs for 3 months or more: – triptans, opioids, ergots or combination analgesic medications on 10 days per month or more or – paracetamol, aspirin or an NSAID, either alone or any combination, on 15 days per month or more.</p>		
<p>NICE CG150 (1.3.14) Do not offer ergots or opioids for the acute treatment of migraine.</p>		
Analgesics		
<p>A simple analgesic such as aspirin, paracetamol (preferably in a soluble or dispersible form) or an NSAID is often effective; concomitant antiemetic treatment may be required.</p>		
	Aspirin OTC tablets 300mg soluble tablets 300mg	
	Ibuprofen OTC tablets 200mg, 400mg, 600mg	
	Naproxen U tablets 250mg, 500mg	
	Diclofenac sodium U suppositories 100mg	MHRA: Diclofenac: new contraindications and warnings, 2014
	Paracetamol OTC tablets: 500mg soluble tablets: 500mg	
Antiemetics		
	Domperidone tablets: 10mg	MHRA DSU: Domperidone: risks of cardiac side effects, May 2014
	Metoclopramide tablets: 10mg	MHRA DSU: Metoclopramide: risk of neurological adverse effects, Aug 2013

	Prochlorperazine Tablets: 5mg U buccal tablets: 3mg OTC	
Combined preparations		
	Aspirin with metoclopramide (MigraMax®) sachets: 900mg/10mg	MHRA DSU: Metoclopramide: risk of neurological adverse effects, Aug 2013
Do Not Prescribe	Paracetamol with isometheptene 325mg/65mg	Criterion 1 (see RAG list)
	Paracetamol with buclizine and codeine Migralve® (all presentations)	Criterion 1 (see RAG list)
	Ergotamine-containing products (e.g. Migril®)	Criterion 1 (see RAG list)
5HT1-receptor agonists (triptans)		
<p>In patients who do not respond to one 5HT1-receptor agonist, a different 5HT1-receptor agonist should be tried as response can be variable between patients. Subcutaneous sumatriptan or nasal zolmitriptan can be given to patients who present with early vomiting or who have severe migraine attacks.</p>		
First choice oral	Sumatriptan tablets: 50mg OTC , 100mg	
Alternatives oral	Zolmitriptan tablets: 2.5mg orodispersible tablets: 5mg	
	Frovatriptan tablets: 2.5mg	
	Naratriptan tablets: 2.5mg	
	Rizatriptan orodispersible tablets: 5mg, 10mg tablets: 10mg	
First choice nasal	Zolmitriptan nasal spray: 5mg per actuation	Consider if vomiting restricts oral treatment, see CKS prescribing information .
Alternative nasal	Sumatriptan nasal spray: 10mg per actuation, 20mg per actuation	

Subcutaneous injection	Sumatriptan subcutaneous injection: 6mg/0.5mL syringe subcutaneous injection: 3mg/0.5mL syringe	
4.7.4.2 Prophylaxis of migraine		
NICE CG150 (1.3.19) Do not offer gabapentin for the prophylactic treatment of migraine		
First choice	Propranolol MR capsules: 80mg, 160mg	
Alternatives	Metoprolol tablets: 50mg, 100mg	If intolerant of propranolol
	Topiramate tablets: 25mg, 50mg, 100mg capsules 15mg	G_n MHRA DSU: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review, Jan 2021
	Zonisamide U capsules: 25mg, 50mg, 100mg	G_n following specialist advice If intolerant of topiramate MHRA DSU: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review, 2021
	Amitriptyline tablets: 10mg, 25mg, 50mg	
	Nortriptyline U tablets: 10mg, 25mg	G_n If intolerant of amitriptyline
	Candesartan U tablets: 2mg, 4mg, 8mg, 16mg	G_n
	Flunarizine U	R
	Botulinum toxin type A (Botox®) 50-unit vial, 100-unit vial, 200-unit vial	R NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
	Erenumab ▼ 70 mg, 140 mg pre-filled pen or syringe	R NICE TA682: Erenumab for preventing migraine
	Fremanezumab ▼ 225 mg pre-filled pen or syringe	R NICE TA764: Fremanezumab for preventing migraine

	Galcanezumab ▼ 120 mg pre-filled pen	R NICE TA659: Galcanezumab for preventing migraine
4.7.4.3 Cluster headache and the trigeminal autonomic cephalalgias		
NICE CG150 (1.3.32) Do not offer paracetamol, NSAIDs, opioids, ergots or oral triptans for the acute treatment of cluster headache.		
Acute treatment	Sumatriptan subcutaneous injection: 6mg/0.5mL syringe subcutaneous injection: 3mg/0.5mL syringe U	
	Zolmitriptan nasal spray: 5mg per actuation U	
	Sumatriptan nasal spray: 10mg per actuation, 20mg per actuation U	
	Oxygen	Follow local prescribing rules
Prophylaxis	Verapamil U tablets: 40mg, 80mg, 120mg, 160mg modified release tablets/capsules: 120mg, 180mg, 240mg	G_n following specialist advice
Tension headache		
NICE CG150 (1.2.7) Do not offer opioids for the acute treatment of tension-type headache		
Acute treatment	Paracetamol Aspirin NSAIDs	As above, see 4.7.4.1
Prophylaxis	Amitriptyline tablets: 10mg, 25mg, 50mg	

BNF Chapter	4 Central nervous system	
Section	4.8 Antiepileptic drugs	
Subsection	4.8.1 Control of the epilepsies	
<p>Initiation and withdrawal of therapy must only be managed by a specialist.</p> <p>Drugs that are not routinely prescribed are not included in the formulary however if a specialist recommends a drug and it is listed as 'G_n following specialist advice' within the RAG list then the patient can be prescribed that treatment.</p> <p>NICE CG137 The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care</p> <p>MHRA DSU: Antiepileptic drugs: Updated advice on switching between different manufacturers' products, Nov 2017</p> <p>Category 1 – Ensure that the patient is maintained on a specific manufacturer’s product.: carbamazepine, phenobarbital, phenytoin, primidone</p> <p>Category 2 - Base the need for continued supply of a particular manufacturer’s product on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. Take into account patient/carer-related factors such as their negative perceptions about alternative products and/or other issues related to the patient should also be taken into account: clobazam, clonazepam, eslicarbazepine, lamotrigine, oxcarbazepine, perampanel, retigabine, rufinamide, topiramate, valproate, zonisamide</p> <p>Category 3 – The potential for clinically relevant differences to exist between different manufacturers’ products is considered to be extremely low. However, consider other patient/carer-related factors, such as negative perceptions about alternative products and/or other issues related to the patient (e.g. patient anxiety, risk of confusion or dosing errors): brivaracetam, ethosuximide, gabapentin, lacosamide, levetiracetam, pregabalin, tiagabine, vigabatrin</p> <p>MHRA DSU: St Johns Wort may interact with antiepileptics, Nov 2007</p> <p>MHRA DSU: Antiepileptics adverse effects on bone, April 2009</p> <p>MHRA DSU: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review, January 2021</p>		
Most commonly prescribed		
Alphabetical order	<p>Carbamazepine</p> <p>MR tablets: 200mg, 400mg</p> <p>tablets: 100mg, 200mg, 400mg</p>	<p>G_n following specialist advice</p> <p>MHRA DSU: Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions, Dec 2012</p>
	<p>Lamotrigine</p> <p>tablets: 25mg, 50mg, 100mg, 200mg</p> <p>dispersible tablets: 25mg, 100mg</p>	<p>G_n following specialist advice</p>
	<p>Levetiracetam</p> <p>tablets: 250mg, 500mg, 750mg, 1g</p> <p>oral solution: 100mg/ml</p>	<p>G_n following specialist advice</p>

	<p>Sodium valproate EC tablets 200mg, 500mg MR tablets: 200mg, 300mg, 500mg SF liquid: 200mg/5ml</p>	<p>G_n following specialist advice</p> <p>MHRA Drug Safety Updates:</p> <ul style="list-style-type: none"> • Valproate medicines (Epilim▼, Depakote▼): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met (April 2018) • Valproate medicines (Epilim▼, Depakote▼): Pregnancy Prevention Programme materials online (May 2018) • Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers (Sept 2018) • Valproate medicines: are you in acting in compliance with the pregnancy prevention measures? (Dec 2018)
<p>Other drugs</p>		
<p>Alphabetical order</p>	<p>Cenobamate tablets: 50mg, 100mg, 150mg, 200mg</p>	<p>G_n following specialist initiation. To be initiated by a tertiary epilepsy service, as per NICE guidance.</p> <p>NICE TA753: Cenobamate for treating focal onset seizures in epilepsy</p>
	<p>Clobazam tablets: 10mg</p>	<p>G_n following specialist advice</p>
	<p>Clonazepam tablets: 500microgram, 2mg</p>	<p>G_n following specialist advice</p> <p>MHRA DSU: Drugs and driving: blood concentration limits set for certain drugs, Feb 2015</p>
	<p>Gabapentin capsules: 100mg, 300mg, 400mg</p>	<p>G_n following specialist advice</p> <p>MHRA DSU: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements, April 2019</p> <p>MHRA DSU: Gabapentin (Neurontin): risk of severe respiratory depression, Oct 2017</p>
	<p>Oxcarbazepine tablets: 150mg, 300mg, 600mg suspension 300mg/5ml</p>	<p>G_n following specialist advice</p> <p>MHRA DSU: Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions, Dec 2012</p>
	<p>Phenobarbital tablets: 15mg, 30mg, 60mg</p>	<p>G_n following specialist advice</p>

	<p>Phenytoin capsules: 25mg, 50mg, 100mg suspension: 30mg/5ml</p>	<p>G_n following specialist advice MHRA DSU: Risk of Stevens-Johnson syndrome, Jan 2010</p>
	<p>Pregabalin capsules: 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg</p>	<p>G_n following specialist advice MHRA DSU: Pregabalin, gabapentin and risk of abuse and dependence: new scheduling requirements, April 2019 MHRA DSU: Pregabalin (Lyrica): reports of severe respiratory depression, Feb 2021 MHRA DSU: Pregabalin (Lyrica): findings of safety study on risks during pregnancy, April 2022</p>
	<p>Primidone tablets: 50mg, 250mg</p>	<p>G_n following specialist advice</p>
	<p>Topiramate tablets: 25mg, 50mg, 100mg, 200mg</p>	<p>G_n following specialist advice</p>
	<p>Zonisamide capsules: 25mg, 50mg, 100mg</p>	<p>G_n following specialist advice</p>
<p>Grey drugs Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population</p>	<p>Cannabidiol (Epidyolex®) For children and adults with rare, severe forms of drug-resistant epilepsy, when used within its marketing authorisation.</p>	<p>R Criterion 3 (see RAG list) NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome NICE NG144: Cannabis-based medicinal products</p>
	<p>Lacosamide tablets: 50mg, 100mg, 150mg, 200mg oral solution: 10mg/ml</p>	<p>G_n following specialist advice Criterion 2 (see RAG list)</p>
	<p>Perampanel tablets: 2mg, 4 mg, 6 mg, 8mg, 10mg, 12mg oral suspension: 0.5mg/ml Only for use as an option for patients with highly refractory epilepsy who are unable to tolerate at least two other more established adjunctive therapies.</p>	<p>G_n following specialist advice Criterion 2 (see RAG list)</p>

	<p>Rufinamide</p> <p>tablets: 100mg, 200mg, 400mg</p> <p>Only for use as an adjunct in patients with Lennox-Gastaut syndrome who have failed treatment with, or are intolerant of, alternative traditional antiepileptic drugs.</p>	<p>G_n following specialist initiation</p> <p>Criterion 2 (see RAG list)</p>
Do Not Prescribe	<p>Cannabis-derived, cannabis-based and hemp products</p> <p>With the exception of Epidyolex (see above) and nabilone (see chapter 8)</p>	<p>Criterion 1 (see RAG list)</p> <p>NICE NG144: Cannabis-based medicinal products</p>
Subsection	4.8.2 Drugs used in status epilepticus	
First choice	<p>Midazolam hydrochloride</p> <p>oromucosal solution 5mg/ml: 2ml syringe (Buccolam▼)</p>	<p>G_n specialist initiation</p> <p>MHRA DSU: Buccal midazolam, Oct 2011</p>
For use in palliative care	<p>Midazolam</p> <p>Injection 5mg/ml</p>	<p>G_n See GMMMG Palliative Care Pain and Symptom Control Guidelines for Adults</p>
Alternatives	<p>Diazepam</p> <p>rectal tubes: 2.5mg, 5mg, 10mg</p>	<p>MHRA DSU: Drugs and driving: blood concentration limits set for certain drugs, Feb 2015</p>

Chapter	4. Central nervous system	
Section	4.9 Drugs used in parkinsonism and related disorders	
<p>Drugs that are not routinely prescribed are not included in the formulary however if a specialist recommends a drug and it is listed as G_n following specialist advice' within the RAG list then the patient can be prescribed that treatment.</p> <p>NICE CG35: Parkinson's disease states that it is not possible to identify a universal first-choice drug therapy for people with PD. The choice of drug first prescribed should take into account:</p> <ul style="list-style-type: none"> clinical and lifestyle characteristics patient preference, after the patient has been informed of the short and long-term benefits and drawbacks of the drug classes. <p>Brand prescribing may be considered where differences in appearance of a medication may cause a patient anxiety or where familiarity with a particular product in a particular device is important e.g. with apomorphine.</p>		
Subsection	4.9.1 Dopaminergic drugs used in Parkinson's disease	
<p>MHRA (2007) Dopamine agonists: pathological gambling, increased libido and hypersexuality</p>		
Dopamine-receptor agonists		
First line	Pramipexole tablets: 88microgram, 180microgram, 350microgram, 700microgram	G_n following specialist advice
	Ropinirole tablets: 250microgram, 500microgram, 1mg, 2mg, 5mg	G_n following specialist advice
	Rotigotine 24 hour patch: 1mg, 2mg, 4mg, 6mg, 8mg	G_n following specialist advice For use when more established oral dopamine agonists are ineffective or swallowing problems are present.
Second line	Pramipexole modified release tablets: 260microgram, 520microgram, 1.05mg, 1.57 mg, 2.1mg, 3.15mg	G_n following specialist advice
	Ropinirole modified release tablets: 2mg, 4mg, 8mg	G_n following specialist advice
Third line	<p>MHRA DSU: Ergot-derived dopamine agonists: risk of fibrotic reactions, Oct 2008</p>	
	Apomorphine injection : 10mg/ml : 2ml amp, 5ml amp pens: 10mg/ml: 3ml pen injector pre-filled syringes: 5mg/ml: 10ml PFS	<div style="text-align: center;">A</div> <p>MHRA DSU: Apomorphine with domperidone: minimising risk of cardiac side effects (April 2016)</p> <p>MHRA DSU: Dopamine agonists: pathological gambling, increased libido, and hypersexuality (August 2007)</p>

Levodopa		
First line (levodopa with dopa-decarboxylase inhibitor)	Co-beneldopa capsules: 12.5/50, 25/100, 50/200 dispersible tablets 12.5/50, 25/100 modified release capsules: 25/100	G_n following specialist advice
	Co-careldopa tablets: 10/100, 25/100, 25/250 modified release tablets:25/100, 50/200	G_n following specialist advice
	Co-careldopa with entacapone Stalevo – see BNF for various strengths	G_n following specialist advice
Do Not Prescribe	Co-careldopa intestinal gel (Duodopa®)	<u>Criterion 3 (see RAG list)</u>
Monoamine-oxidase-B inhibitors		
	Rasagiline tablets: 1mg	G_n following specialist advice
	Safinamide▼ tablets : 50mg, 100mg	G_n following specialist advice
	Selegiline tablets: 5mg, 10mg	G_n following specialist advice
Catechol-O-methyltransferase inhibitors		
First line	Entacapone tablets: 200mg	G_n following specialist advice
Grey drugs Items which are listed as Grey are deemed not suitable for routine prescribing but may be suitable for a defined patient population	Opicapone▼ hard capsules: 50mg For use only where entacapone (either alone or in combination) is considered not suitable.	G_n following specialist advice <u>Criterion 2 (see RAG list)</u>
Amantadine		
	Amantadine capsules: 100mg oral solution: 50mg/5ml	G_n following specialist advice

Subsection	4.9.2 Antimuscarinic drugs used in parkinsonism	
	Not recommended due to association with cognitive impairment. Not recommended in the elderly due to toxicity and risk of aggravating dementia.	
First choice	Procyclidine tablets: 5mg sugar free syrup: 2.5mg/5ml, 5mg/5ml	G_n
Alternatives	Orphenadrine tablets: 50mg	
Subsection	4.9.3 Drugs used in essential tremor, chorea, tics and related disorders	
	Riluzole tablets: 50mg oral suspension: 5mg/ml	A SCP: riluzole for amyotrophic lateral sclerosis. NICE TA20: Riluzole for motor neurone disease NICE NG42: MND: assessment and management
Additional Notes		
<p>Propranolol (section 2.4) may be useful in treating essential tremor or tremors associated with anxiety of thyrotoxicosis.</p> <p>Specialist centres will advise on suitable alternative options for essential tremor, chorea, tics and related disorders.</p>		
	Botulinum toxin type A (Xeomin [®]) 50, 100 or 200 units, powder for solution for injection	R NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea

BNF Chapter	4 Central Nervous System	
Section	4.10 Drugs used in substance dependence	
Subsection	4.10.1 Alcohol dependence	
	NICE CG115: Alcohol dependence and harmful alcohol use NICE NG58: Coexisting severe mental illness and substance misuse: community health and social care services	
Alphabetical order	Acamprosate gastro-resistant tablets: 333mg	 In conjunction with specialist service
	Chlordiazepoxide capsules: 5mg, 10mg tablets: 5mg, 10mg	 In conjunction with specialist service For detoxification as a short course to aid alcohol withdrawal
	Disulfiram tablets: 200mg	 A Patient must be stabilised prior to transfer of prescribing. (> 3 months) GM shared care protocol: Disulfiram in the treatment of alcohol dependence
	Nalmefene▼ tablets: 18mg	 In conjunction with specialist alcohol service NICE (2014): Nalmefene for reducing alcohol consumption in people with alcohol dependence, TA325
	Naltrexone tablets: 50mg	 R Recommended in NICE guidance for max 6 months duration. To remain under specialist community alcohol teams

Subsection	4.10.2 Cigarette smoking	
	Therapy is chosen according to the smoker's likely compliance, availability of counselling and support, previous experience of smoking cessation aids, contra-indications and adverse effects of the products and smokers preference.	
	MHRA DSU: Smoking and smoking cessation: clinically significant interactions with commonly used medicines, Oct 2009 NICE PH45: Tobacco: harm-reduction approaches to smoking NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence GMMMG Tobacco dependency treatment guideline	
First choice	Nicotine patches 16 hour: 5mg, 10mg, 15mg, 25mg patches 24 hour: 7mg, 14mg, 21mg chewing gum: 2mg, 4mg lozenges: 2mg, 4mg inhalator cartridges: 10mg, 15mg oral spray: 1mg	
Alternatives	Varenicline 2 week starter pack: 11x500 microgram with 14x1mg tablets tablets: 500mcg, 1mg	NICE TA123: Varenicline for smoking cessation Varenicline should normally be prescribed only as part of a programme of behavioural support. Clinicians should be aware of the possible emergence of significant depressive symptoms when using varenicline
	Bupropion hydrochloride modified release tablets: 150mg	MHRA DSU: Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs, Nov 2020
Do Not Prescribe	e-Voke® electronic inhaler and Voke® inhaler Further data are required evaluating the use of Voke & e-Voke as a stop smoking aid, and comparing their efficacy to established smoking cessation treatments, prior to their use in the GM region.	Criterion 1 (see RAG list)
Additional Notes		
The combination of NRT with varenicline▼ or bupropion is not recommended		

Subsection	4.10.3 Opioid dependence	
	NICE (2007): Methadone and buprenorphine for the management of opioid dependence (TA114)	
First choice	<p>Methadone oral solution: 1mg/1ml</p>	<p>MHRA DSU: Drugs and driving: blood concentration limits set for certain drugs, Feb 2015</p> <p>RAG status depends on local commissioning arrangements for substance misuse or if GP with specialist interest</p>
Alternatives	<p>Buprenorphine sublingual tablets: 400microgram, 2mg, 8mg oral lyophilisate (Espranor®): 2mg, 8mg</p>	<p>Prescribe by brand; due to difference in bioavailability Espranor® is not dose-equivalent with sublingual products. Patient to be maintained on their normal brand of buprenorphine if admitted as an inpatient</p> <p>RAG status depends on local commissioning arrangements for substance misuse or if GP with specialist interest</p>
	<p>Lofexidine tablets: 200microgram</p>	Lofexidine for detoxification
	<p>Naltrexone tablets: 50mg</p>	<p>R For alcohol disorders</p> <p>NICE TA115: Naltrexone for the management of opioid dependence</p> <p>For opioid dependence: RAG status depends on local commissioning arrangements for substance misuse or if GP with specialist interest</p>

BNF Chapter	4 Central Nervous System	
Section	4.11 Drugs for dementia	
	NICE NG97: Dementia: assessment, management and support for people living with dementia and their carers NICE TA217: Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine	
First choice	Donepezil tablets: 5mg, 10mg SF orodispersible tablets: 5mg, 10mg	 GMMMG information for primary care prescribers
Alternatives	Galantamine tablets: 8mg, 12mg modified release capsules: 8mg, 16mg, 24mg	 GMMMG information for primary care prescribers
	Rivastigmine capsules: 1.5mg, 3mg, 4.5mg, 6mg patches: 4.6mg/24hours, 9.5mg/24 hours	 Local commissioning arrangements may vary and in some localities this is green (specialist advice); please check with CCG. MHRA DSU: Rivastigmine transdermal patch: risk of medication errors, June 2010 GMMMG information for primary care prescribers
	Memantine tablets: 10mg, 20mg	 MHRA DSU: Memantine pump device: risk of medication errors Nov 2010 GMMMG information for primary care prescribers